title: Peripheral leukocyte counts and outcomes after intracerebral hemorrhage.
abstract: BACKGROUND
  Intracerebral hemorrhage (ICH) is a devastating disease that carries a 30 day mortality of approximately 45%. Only 20% of survivors return to independent function at 6 months. The role of inflammation in the pathophysiology of ICH is increasingly recognized. Several clinical studies have demonstrated an association between inflammatory markers and outcomes after ICH; however the relationship between serum biomarkers and functional outcomes amongst survivors has not been previously evaluated. Activation of the inflammatory response as measured by change in peripheral leukocyte count was examined and assessment of mortality and functional outcomes after ICH was determined.
  
  
  RESULTS
  Patients with spontaneous ICH admitted to a tertiary care center between January 2005 and April 2010 were included. The change in leukocyte count was measured as the difference between the maximum leukocyte count in the first 72 hours and the leukocyte count on admission. Mortality was the primary outcome. Secondary outcomes were mortality at 1 year, discharge disposition and the modified Barthel index (MBI) at 3 months compared to pre-admission MBI. 423 cases were included. The in-hospital mortality was 30.4%. The change in leukocyte count predicted worse discharge disposition (OR = 1.258, p = 0.009). The change in leukocyte count was also significantly correlated with a decline in the MBI at 3 months. These relationships remained even after removal of all patients with evidence of infection.
  
  
  CONCLUSIONS
  Greater changes in leukocyte count over the first 72 hours after admission predicted both worse short term and long term functional outcomes after ICH.
authors.affiliation: Department of Neurology, University of Connecticut, 263 Farmington Avenue, Farmington, CT, USA.
authors.forename: Shruti
authors.initials: S
authors.lastname: Agnihotri
authors.forename: Alexandra
authors.initials: A
authors.lastname: Czap
authors.forename: Ilene
authors.initials: I
authors.lastname: Staff
authors.forename: Gil
authors.initials: G
authors.lastname: Fortunato
authors.forename: Louise D
authors.initials: LD
authors.lastname: McCullough
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000378:metabolism; D002543:Cerebral Hemorrhage / Q000097:blood* / Q000276:immunology* / Q000401:mortality / Q000503:physiopathology*; D005260:Female; D017052:Hospital Mortality; D006801:Humans; D007249:Inflammation / Q000276:immunology; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers
references.citation: Lancet. 2009 May 9;373(9675):1632-44
references.pmid: 19427958
references.citation: Stroke. 2011 May;42(5):1230-6
references.pmid: 21474813
references.citation: J Stroke Cerebrovasc Dis. 1999 Jan-Feb;8(1):1-8
references.pmid: 17895130
references.citation: Stroke. 2011 Jun;42(6):1781-6
references.pmid: 21527759
references.citation: J Cereb Blood Flow Metab. 2007 May;27(5):894-908
references.pmid: 17033693
references.citation: Stroke. 1995 Jun;26(6):1020-3
references.pmid: 7762017
references.citation: Med Hypotheses. 2010 Jan;74(1):63-6
references.pmid: 19716661
references.citation: Lancet Neurol. 2010 Feb;9(2):167-76
references.pmid: 20056489
references.citation: Circulation. 2011 Feb 1;123(4):e18-e209
references.pmid: 21160056
references.citation: Neurology. 2006 Apr 25;66(8):1182-6
references.pmid: 16636234
references.citation: Neurology. 2004 Aug 10;63(3):461-7
references.pmid: 15304576
references.citation: Lancet Neurol. 2006 Jan;5(1):53-63
references.pmid: 16361023
references.citation: Brain Res. 2000 Jul 14;871(1):57-65
references.pmid: 10882783
references.citation: J Neurol Neurosurg Psychiatry. 1990 Jan;53(1):16-22
references.pmid: 2303826